Amyris
Aug 4, 2016

Amyris Reports Second Quarter 2016 Results

Strongest Operational Execution to Date while Successfully Moving the Business Beyond Biofuels

EMERYVILLE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced financial results for the second quarter ended June 30, 2016.

"We're very pleased with reaching our best ever quarter of signing new collaborations that have already funded more than $20 million of payments this year and are expected to more than underpin our full year targets," said John Melo, Amyris President & CEO. "We are encouraged by these results and our success in delivering on our stated milestones and goals thus far this year.  Additional progress in the coming months is anticipated to further grow our customer base, improve our balance sheet and further position the company as the leader in industrial biotechnology."

Key Highlights

Other key operating and development highlights during the second quarter and more recently included:

Financial Performance

Second Quarter 2016

First Half 2016

FINANCIAL RESULTS AND NON-GAAP INFORMATION

Condensed consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. Management believes that it is useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate management's internal comparisons to Amyris's historical performance as well as comparisons to the operating results of other companies. Management believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision-making.

Adjusted net loss is calculated by taking GAAP net loss and excluding stock-based compensation and gains and losses from changes in fair value of derivatives and debt extinguishment.

Non-GAAP revenue represents GAAP product revenue plus the cash received from collaborations. Non-GAAP revenue is calculated using GAAP revenues and adding the related changes in accounts receivable and deferred revenue related to revenue recognized for these collaborations and grants to equal funds received during the period, along with any funding associated with collaborations.

Non-GAAP financial information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP in order to understand Amyris's operating performance. A reconciliation of the non-GAAP financial measures presented in this release, including non-GAAP net loss, non-GAAP revenue, and other measures, is provided in the tables attached to this press release.

QUARTERLY CONFERENCE CALL TODAY

Amyris will discuss these results and provide a business update in a conference call scheduled for 4:30 p.m. ET (1:30 p.m. PT) today. Investors may access the call by dialing (866) 516-3867, participant passcode: 49059751.

A live audio webcast of this conference call and accompanying presentation is also available by visiting the investor relations section of the company's website at http://investors.amyris.com. A replay of the webcast will be available at the investor relations section of the company's website approximately two hours after the conclusion of the call.

About Amyris
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected increase in revenues in the second half of 2016 as a result of collaborations signed in the second quarter, the advancement of the commercialization of Amyris's technology platform, the anticipated growth of Amyris's customer base, the anticipated improvement of Amyris's balance sheet, Amyris's position as a leader in industrial biotechnology, the expected benefits and results of Amyris's relationship with Ginkgo Bioworks, including delivering more new cultured ingredients into the global market over the next three years than the entire industry has achieved in the last ten years and amending Amyris's senior secured credit facility, the commercialization timeline for Amyris's fragrance product with Takasago International Corporation, increased market access for and accelerated revenue growth of Novvi LLC, continued strong farnesene demand, potentially opening a new area of compounds previously not accessible for new drug discovery, the biopharma market being positioned to become Amyris's largest opportunity for collaborations, actions to reduce operating expenses, and expectations regarding Amyris's ability to execute its 2016 plan, including non-core business divestments in Q3, further operating expense improvements, amending near-term debt agreements, and cash generation from collaborations), that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including Amyris's liquidity and ability to fund operating and capital expenses, timing and execution risks associated with manufacturing, uncertainty regarding consummating proposed transactions, including the timing thereof, and growth in sales, potential delays or failures in development, production and commercialization of products, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on May 10, 2016. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo, µPharm, and Neossance Squalane are registered trademarks of Amyris, Inc.

            -Financial Tables Attached-

Amyris, Inc.      
Condensed Consolidated Balance Sheets     
(In thousands)     
         
     June 30, December 31, 
      2016   2015  
     (Unaudited)   
Assets      
Current assets:     
 Cash, cash equivalents and short-term investments $  2,507  $  13,512  
 Restricted cash  275     216  
 Accounts receivable, net  4,070   4,004  
 Related party accounts receivable  587   1,176  
 Inventories, net  9,996   10,886  
 Prepaid expenses and other current assets  4,043   4,583  
  Total current assets  21,478   34,377  
Property, plant and equipment, net  65,200   59,797  
Restricted cash    5,958     957  
Equity and loans in affiliate    34     68  
Other assets  12,633   10,357  
Goodwill and intangible assets  560   560  
Total assets $   105,863   $   106,116   
         
Liabilities and stockholders' deficit     
Current liabilities:     
 Accounts payable $  9,808  $  7,943  
 Deferred revenue    7,717     6,509  
 Accrued and other current liabilities    30,858     24,268  
 Capital lease obligation, current portion    1,370     523  
 Debt, current portion    54,421     36,281  
 Related party debt    25,558     -   
  Total current liabilities    129,732     75,524  
Capital lease obligation, net of current portion    99     176  
Long-term debt, net of current portion    62,150     72,826  
Related party debt    39,263     42,867  
Deferred rent, net of current portion    9,338     9,682  
Deferred revenue, net of current portion    4,469     4,469  
Derivative liabilities    6,752     51,439  
Other liabilities    3,244     7,589  
  Total liabilities    255,047     264,572  
         
Amyris, Inc. stockholders' deficit    (149,070)    (158,065) 
Noncontrolling interest    (114)    (391) 
  Total stockholders' deficit     (149,184)    (158,456) 
         
Total liabilities and stockholders' deficit $   105,863   $   106,116   
         

 

Amyris, Inc.          
Condensed Consolidated Statement of Operations        
(Unaudited)         
(In thousands, except per share data)        
   Three Months Ended Six Months Ended 
   June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015 
Revenues         
 Renewable product sales$  4,922  $  3,340  $  8,062  $  5,435  
 Grants and collaborations revenue   4,677     4,503     10,347     10,280  
 Total revenues    9,599     7,843     18,409     15,715  
Costs and operating expenses        
 Cost of products sold   7,891     10,959     19,068     17,602  
 Research and development (1)   13,176     11,168     25,082     23,178  
 Sales, general and administrative (1)   11,408     14,375     23,674     28,756  
 Total costs and operating expenses   32,475     36,502     67,824     69,536  
Loss from operations    (22,876)    (28,659)    (49,415)    (53,821) 
Other income (expense):        
 Gain (loss) from change in fair value of derivatives & debt extinguishment (2)   20,934     28,834     42,612     11,422  
 Loss on extinguishment of debt   (433)    -      (649)    -   
 Other income (expense), net (3)   (11,053)    (46,595)    (21,169)    (55,360) 
 Total other income (expense)   9,448     (17,761)    20,794     (43,938) 
Loss before income taxes and loss from investments in affiliates   (13,428)    (46,420)    (28,621)    (97,759) 
Provision for income taxes   (138)    (121)    (253)    (236) 
Net loss before loss from investments in affiliates   (13,566)    (46,541)    (28,874)    (97,995) 
Loss from investments in affiliates   -      (621)    -      (1,429) 
Net loss $  (13,566) $  (47,162) $  (28,874) $  (99,424) 
Net loss attributable to noncontrolling interest   -      32     -      54  
Net loss attributable to Amyris, Inc. common stockholders$  (13,566) $  (47,130) $  (28,874) $  (99,370) 
Net loss per share attributable to common stockholders,  basic$  (0.06) $  (0.59) $  (0.13) $  (1.25) 
Net loss per share attributable to common stockholders, diluted (4)$  -   $  (0.62) $  -   $  (1.25) 
Weighted-average shares of common stock outstanding used in         
 computing net loss per share of common stock:        
 Basic  223,112,019   80,041,152   216,393,705
   79,633,864  
 Diluted (4)  
   87,421,439   
   79,633,864  
           
           
 (1)Includes stock-based compensation expense of the following for the periods presented:       
           
 Research and development $  485  $  530  $  977  $  1,246  
 Sales, general and administrative   1,304     1,526     2,863     3,462  
   $  1,789  $  2,056  $  3,840  $  4,708  
           
 (2)For the second quarter of 2016 and 2015, the Company recorded a non-cash gain from revaluation of its derivative liabilities, which was triggered by certain features of outstanding convertible notes (related to change in control protection and price-based anti-dilution adjustment provisions). The valuation of these derivative liabilities decreased in the second quarter of 2016 and 2015 primarily as a result of a decrease in Amyris's stock price since March  31, 2016 and 2015,  respectively. 
 (3)Other income (expense), net for the second quarter of 2015 includes $36.6 million charge related to the acceleration of debt discount accretion associated with a debt conversion transaction. 
 (4)The Company is in process of calculating the fully-diluted earnings per share for the periods ended June 30, 2016, which will be included in the Company's 10-Q to be filed by August 9. 
           
           
Amyris, Inc.          
Reconciliation of GAAP to Non-GAAP Financial Information        
(Unaudited)         
(In thousands, except per share data)        
   Three Months Ended Six Months Ended 
   June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015 
           
Net loss attributable to Amyris, Inc. common stockholders (GAAP)$  (13,566) $  (47,130) $  (28,874) $  (99,370) 
 Stock-based compensation expense   1,789     2,056     3,840     4,708  
 Gain from change fair in value of derivative & debt extinguishment   (20,934)    (28,834)    (42,612)    (11,422) 
 Acceleration of debt discount accretion associated with the debt         
 conversion transaction   -      36,570     -      36,570  
Net loss attributable to Amyris, Inc. common stockholders (Non-GAAP)$   (32,711) $   (37,338) $   (67,646) $   (69,514) 
           
Net loss per share attributable to Amyris, Inc. common stockholders,        
 basic (GAAP) $  (0.06) $  (0.59) $  (0.13) $  (1.25) 
 Stock-based compensation expense$  0.01  $  0.03  $  0.02  $  0.06  
 Gain (loss) from change fair in value of derivative & debt extinguishment$  (0.09) $  (0.36) $  (0.20) $  (0.14) 
 Acceleration of debt discount accretion associated with the debt        
 conversion transaction$  -   $  0.46  $  -   $  0.46  
Net loss per share attributable to Amyris, Inc. common stockholders,        
 (Non-GAAP) $   (0.15) $   (0.47) $   (0.31) $   (0.87) 
           

 

Amyris, Inc.          
Reconciliation of GAAP to Non-GAAP Financial Information         
(Unaudited)         
(In thousands)         
            
    Three Months Ended Six Months Ended 
    June 30, 2016 June 30, 2015 June 30, 2016 June 30, 2015 
            
Product sales (GAAP & Non-GAAP)         
 Renewables $  4,922  $  3,340  $  8,062  $  5,435  
Product sales (GAAP & Non-GAAP) $   4,922   $   3,340   $   8,062   $   5,435   
            
Grants and collaborations revenue (GAAP) $  4,677  $  4,503  $  10,347  $  10,280  
 Change in accounts receivable, deferred revenue and fundings associated          
  with collaborations    2,828     (2,637)    (746)    19,765  
Collaborations Inflows (Non- GAAP) (1) $   7,505   $   1,866   $   9,601   $   30,045   
            
Total Revenues (GAAP) $  9,599  $  7,843  $  18,409  $  15,715  
 Change in accounts receivable, deferred revenue and fundings associated          
  with collaborations    2,828     (2,637)    (746)    19,765  
Total Cash Revenue Inflows (Non-GAAP) (1) $   12,427   $   5,206   $   17,663   $   35,480   
            
Costs of products sold (GAAP) $  7,891  $  10,959  $  19,068  $  17,602  
 Other costs/provisions    (1,547)    (2,493)    (3,643)    (1,581) 
 Excess capacity    (1,420)    (1,766)    (4,177)    (5,174) 
 Depreciation and amortization    (914)    (1,146)    (1,730)    (2,403) 
Costs of products sold (Non- GAAP) $   4,010   $   5,554   $   9,518   $   8,444   
            
 Adjusted Gross Profit (Non- GAAP) (2) $   5,589   $   2,289   $   8,891   $   7,271   
 Gross Margin (%) (2)  58.2%  29.2%  48.3%  46.3% 
            
Research and development (GAAP) $  13,176  $  11,168  $  25,082  $  23,178  
 Stock-based compensation expense    (485)    (530)    (977)    (1,246) 
 Depreciation and amortization    (1,676)    (1,847)    (3,478)    (3,732) 
Research and development (Non-GAAP) $   11,015   $   8,791   $   20,627   $   18,200   
            
Sales, general and administrative (GAAP) $  11,408  $  14,375  $  23,674  $  28,756  
 Stock-based compensation expense    (1,304)    (1,526)    (2,863)    (3,462) 
 Depreciation and amortization    (287)    (383)    (565)    (761) 
Sales, general and administrative (Non-GAAP) $   9,817   $   12,466   $   20,246   $   24,533   
            
 (1)The largest differences between the GAAP and non-GAAP collaborations numbers are (i) timing of revenue recognition and (ii) the TOTAL collaboration cash, which is treated as debt for GAAP purposes. 
 
     
   The six months ended June 30, 2016 and 2015, includes zero and $10.8 million, respectively, of funding from TOTAL which is in the form of convertible debt financing as contemplated in the July 2012 Amended Collaboration Agreement with TOTAL. 
     
 (2)Non-GAAP Gross Profit /(Loss) is calculated based on non-GAAP Product Sales & Grants and Collaboration Inflows and Cost of Products Sold, and does not include costs related to collaborations. 

 

Contact:

Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc. 
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com